This federal Project Grant award of $560,000 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a novel triple gene therapy to regenerate cardiac tissue and improve function in patients with ischemic heart failure. The research will be conducted by Baylor College of Medicine and involves combining three modalities: inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing vascularization. The two-phase project will first determine the optimal dosage in rat models, with a goal of achieving a 10-point improvement in ejection fraction. The second phase will then demonstrate the efficacy and initial safety of the therapy delivered through a minimally invasive catheter injection in a pig model and human heart slices. This project has the potential to provide a promising new treatment approach for the irreversible loss of cardiomyocytes caused by myocardial infarction and ischemic heart failure.
Generated 3/25/25, 1:55 AM